drugset
drugset / Trial / NCT07260669

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

NCT07260669 ↗

Phase 2 Recruiting 190 enrolled Gesynta Pharma AB
RandomizedParallel-groupTriple-blindTreatment

Summary

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

Timeline

Start
2025-10-15
Primary completion
2027-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vipoglanstat Small molecule — Oral

Indications

endometriosis